Evidence map›Paper›PMID 24777195›Full record

ArticleBone marrow transplantation2014

Allogeneic haematopoietic SCT for natural killer/T-cell lymphoma: a multicentre analysis from the Asia Lymphoma Study Group.

E Tse, T S Y Chan, L-P Koh, W-J Chng, W-S Kim, T Tang, S-T Lim, A K W Lie, Y-L Kwong

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Allogeneic Hematopoietic Stem Cell Transplantation in Extranodal Natural Killer/T-cell LymphomaTurkish journal of haematology : official journal of Turkish Society of Haematology · 2021
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. How we treat NK/T-cell lymphomas.Journal of hematology & oncology · 2022
    Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Extranodal NK/T cell lymphoma.Blood research · 2020
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

E TseDepartment of Medicine, Queen Mary Hospital, Hong Kong, China.
T S Y ChanDepartment of Medicine, Queen Mary Hospital, Hong Kong, China.
L-P KohDepartment of Haematology-Oncology, National University Cancer Institute, Singapore.
W-J ChngDepartment of Haematology-Oncology, National University Cancer Institute, Singapore.
W-S KimDivision of Hemato-Oncology, Samsung Medical Center, Seoul, Korea.
T TangDepartment of Medical Oncology, National Cancer Centre, Singapore.
S-T LimDepartment of Medical Oncology, National Cancer Centre, Singapore.
A K W LieDepartment of Medicine, Queen Mary Hospital, Hong Kong, China.
Y-L KwongDepartment of Medicine, Queen Mary Hospital, Hong Kong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Eighteen patients (men=14; women=4) with natural killer (NK)/T-cell lymphomas (CR1, N=9; CR2, N=7; PR, N=1; progressive disease, N=1) undergoing allogeneic haematopoietic SCT (HSCT) (myeloablative, N=14; reduced intensity, N=4) were analyzed. With a median follow-up of 20.5 months, the 5-year OS was 57% and 5-year EFS was 51%. The use of the SMILE regimen pre-HSCT was the most important positive prognostic indicator, resulting in significantly superior OS and EFS (P<0.01). Acute GVHD had a significant negative impact on OS (P=0.03). CR1 and CR2 patients had similar survivals, but all patients who were not transplanted in remission died. Chronic GVHD, International Prognostic Index, disease stage, primary sites of involvement, conditioning regimen and source of HSC did not affect survival. Although allogeneic HSCT leads to reasonable survival for NK/T-cell lymphoma patients, results need to be compared with those in patients receiving L-asparaginase-containing regimens. Novel prognostic models incorporating biomarkers, such as circulating EBV DNA, are needed to identify high-risk patients who may benefit from allogeneic HSCT.

Indexed as

AdolescentAdultFemaleHematopoietic Stem Cell TransplantationHumansKiller Cells, NaturalLymphoma, T-CellMaleMiddle AgedTransplantation ConditioningTransplantation, HomologousYoung Adult

Identifiers

PMID24777195

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.